Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

16 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

4 terminated out of 100 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

18%

18 trials in Phase 3/4

Results Transparency

33%

16 of 48 completed with results

Key Signals

16 with results92% success

Data Visualizations

Phase Distribution

59Total
Not Applicable (23)
Early P 1 (4)
P 1 (6)
P 2 (8)
P 3 (14)
P 4 (4)

Trial Status

Completed48
Unknown17
Recruiting15
Active Not Recruiting6
Enrolling By Invitation5
Terminated4

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 48 completed trials

Clinical Trials (100)

Showing 20 of 20 trials
NCT04941599Phase 2RecruitingPrimary

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

NCT05218005Not ApplicableCompletedPrimary

Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia

NCT06331195Not ApplicableActive Not RecruitingPrimary

An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)

NCT05348564Not ApplicableRecruiting

Comparing Direct vs Indirect Methods for Cascade Screening

NCT03832985Early Phase 1Completed

Pediatric Reporting of Adult-Onset Genomic Results

NCT07470723Not ApplicableRecruiting

The ORIGIN-FH Study

NCT05746247Not ApplicableEnrolling By InvitationPrimary

Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics

NCT04272697RecruitingPrimary

EAS Familial Hypercholesterolaemia Studies Collaboration

NCT05952869Phase 3Completed

A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

NCT05614219Not ApplicableRecruitingPrimary

Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.

NCT05750667Not ApplicableEnrolling By InvitationPrimary

Penn Family Screening for Familial Hypercholesterolemia

NCT05367310Active Not RecruitingPrimary

Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia

NCT05238519Phase 3Active Not RecruitingPrimary

Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

NCT06546137Recruiting

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

NCT05695937Not ApplicableCompletedPrimary

Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Patients With Familial Hypercholesterolemia

NCT03747224Phase 1Completed

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

NCT05284513Not ApplicableEnrolling By InvitationPrimary

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

NCT06005597Phase 3Completed

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722Phase 3Completed

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05851066Phase 1Completed

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

Scroll to load more

Research Network

Activity Timeline